‘Transformative’ sickle cell treatment approved for NHS use
- Around 4,000 people with sickle cell disease in England could benefit from a “life-changing” new treatment after it was given the green light for use in the NHS.
- Health leaders said that voxelotor, also known as oxbryta and made by Pfizer, will significantly improve quality of life for patients with the condition.
- The drug works by helping haemoglobin hold on to more oxygen, preventing red blood cells from becoming misshapen, and has been approved for NHS use after a price reduction.
Insights by Ground AI
Does this summary seem wrong?
0 Articles
0 Articles
All
Left
Center
Right
Coverage Details
Total News Sources0
Leaning Left2Leaning Right0Center4Last Updated15 days agoBias Distribution67% Center
Bias Distribution
- 67% of the sources are Center
67% Center
L 33%
C 67%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage